Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Coronavirus COVID-19 Sales & Earnings Commercial

COVID-19 Continues To Drive Demand For Baxter’s Acute Therapies Portfolio

  • News

Executive Summary

Demand for Baxter's acute therapy products helped offset declines across its advanced surgery, pharmaceuticals and medication-delivery businesses in the second quarter.

You may also be interested in...



COVID-19 Lessons: Experts Predict Shift Toward Intermittent Hemodialysis In ICUs

The pandemic may accelerate a move toward versatile, single-solution renal replacement therapy in intensive care.

Baxter Reports $45M Boost From COVID-19 Demand In Q1

The COVID-19 pandemic has increased demand for products from all of Baxter’s businesses except its advanced surgery division. Overall, the diversified company’s global sales were up 8% in the first quarter.

Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio

Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.

Table

View full table

Topics

Related Companies

Tags:
Coronavirus COVID-19 Sales & Earnings Commercial
Latest Headlines

It’s Been Over 1100 Days Since MCIT, Still No TCET In Sight

Mini-Slings Are Comparable To Traditional Ones To Treat Incontinence, FDA Says

Ekso's Exoskeleton Receives Medicare Coverage, Paves Way To Faster Rehabilitation

EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency

See All
UsernamePublicRestriction

Register

MT142507

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By